Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event [Yahoo! Finance]
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 [Yahoo! Finance]
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608